Nemluvio Patient Assistance Program

(nemolizumab-ilto)

Key Takeaways

  1. Nemluvio® (nemolizumab-ilto) is an interleukin-31 (IL-31) receptor antagonist approved for the treatment of prurigo nodularis (PN) in adults and moderate-to-severe atopic dermatitis (eczema) in eligible adults and adolescents.
  2. For atopic dermatitis, Nemluvio is used in combination with topical corticosteroids and/or topical calcineurin inhibitors when topical prescription therapies alone do not adequately control the disease or are not advisable.
  3. Nemluvio does not carry an FDA Boxed Warning. However, patients should be monitored for hypersensitivity reactions, eye disorders, and parasitic (helminth) infections.
  4. Nemluvio is administered by subcutaneous injection, typically every 4 weeks after the initial loading dose, and may be self-administered after appropriate training.
  5. Prescription Hope may help eligible individuals access manufacturer-sponsored patient assistance programs that can make Nemluvio more affordable.

 

Introduction

Chronic inflammatory skin conditions such as prurigo nodularis and moderate-to-severe atopic dermatitis can cause persistent itching, skin damage, and significant effects on sleep and quality of life. When topical prescription therapies do not adequately control symptoms, additional treatment options may be considered.

Nemluvio is a targeted biologic therapy that blocks the interleukin-31 (IL-31) pathway, a key contributor to chronic itching and skin inflammation. It is approved for adults with prurigo nodularis and for eligible adults and adolescents with moderate-to-severe atopic dermatitis in combination with topical therapies.

Prescription assistance programs may help eligible patients obtain Nemluvio at a more affordable cost.

What Is the Nemluvio Patient Assistance Program?

Understanding Nemluvio Prescription Assistance

Unfortunately, many Americans struggle to afford their brand-name medications. As they watch their medication costs rise, they are desperately looking for ways to save.

Manufacturers understand that some of their brand-name medications may be unaffordable for most Americans. To help, they often provide patient assistance programs.

What are patient assistance programs?

These programs offer qualified patients access to brand-name medications at affordable rates.

However, many of these programs are known to be difficult to apply for and complexity.

Thankfully, Prescription Hope offers a solution.

How Expert Advocates Help Make Nemluvio More Affordable

Personalized Medication Assistance

Prescription Hope’s prescription assistance specialists provide prescription application support from start to finish. Our team completes forms, collects documents and signatures, coordinates with healthcare providers and manufacturers, and advocates on your behalf throughout the process.

Ongoing Patient Support

Not only do our patient advocates offer application services, but they also provide long-term medication support services. This includes document updates, issue resolution, yearly renewals, and even refill scheduling.

Nemluvio Price Comparison

vs

Prescription Hope logo

Estimated Retail Price*

$4,356.61

30-Day Supply

Prescription Hope Price

$70

Per Month, NO Matter The Retail Price

*Source: Drugs.com

Navigating Specialty Medication Costs

Qualified patients who enroll with Prescription Hope pay a simple $70.00 per month, per medication – no matter the brand-name medication.

And if we can’t help you save, then you pay nothing!

Nemluvio Patient Assistance Eligibility

General Eligibility Requirements

Who qualifies for Nemluvio assistance?

To determine Nemluvio eligibility, patients should enroll with Prescription Hope to find out more details.

All patient assistance programs maintain specific requirements that fall under several general categories. Some include:

Income: Each program differs in their specific income range for qualification.

Insurance: Each program holds a different insurance coverage status qualification. Some require a qualified patient to have no insurance, while others allow some form of insurance.

Prescription: All patient assistance programs require a valid prescription for their brand-name medication.

Residency: All qualified patients must be legal U.S. residents.

Simple Enrollment With Expert Support

Getting Started With Enrollment

To enroll in Nemluvio assistance, patients should submit their enrollment form to Prescription Hope today. Our process only takes 6 simple steps:

  1. Submit Information: Complete our enrollment form in only a few minutes.
  2. Advocate Contact: Once we receive your completed form, a patient advocate will contact you within 1-2 business days.
  3. Document Collection: Following prequalification, our team collects all necessary documents.
  4. Provider Coordination: A team member will coordinate needed signatures with your healthcare provider.
  5. Program Submission: We then submit your application to the manufacturer and coordinate with them throughout the processing stage.
  6. Medication Delivery: After approval, qualified patients typically receive their medications within 2 weeks. All medication ships directly to a patient’s door or doctor’s office.

Prescription Hope is not a pharmacy or manufacturer, and therefore does not handle medications at any time.

Understanding Nemluvio

How Nemluvio Works

Nemluvio contains nemolizumab-ilto, a humanized monoclonal antibody that binds to the interleukin-31 receptor alpha (IL-31RA).

IL-31 is a cytokine that plays a central role in:

  • Chronic itching (pruritus)
  • Skin inflammation
  • Disruption of the skin barrier

By blocking IL-31 receptor signaling, Nemluvio helps reduce pruritus and inflammation, which contributes to improvement of skin lesions associated with prurigo nodularis and atopic dermatitis.

What Conditions Does Nemluvio Treat?

Nemluvio is FDA-approved for:

  • Treatment of adults with prurigo nodularis (PN)
  • Treatment of adults and pediatric patients 12 years of age and older weighing at least 30 kg with moderate-to-severe atopic dermatitis (eczema), in combination with topical corticosteroids and/or topical calcineurin inhibitors, when the disease is not adequately controlled with topical prescription therapies

Nemluvio is indicated for patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Benefits of Treatment

For appropriate patients, Nemluvio may:

  • Significantly reduce chronic itching
  • Improve skin lesions associated with prurigo nodularis
  • Improve signs and symptoms of moderate-to-severe atopic dermatitis
  • Reduce scratching that contributes to skin damage
  • Improve sleep disturbances caused by persistent itching
  • Provide targeted biologic therapy directed at the IL-31 pathway

Clinical studies demonstrated meaningful reductions in itch and skin disease severity in many patients, although individual responses vary.

Important Safety Information and Side Effects

Nemluvio does not carry an FDA Boxed Warning.

Contraindications

Nemluvio is contraindicated in patients with:

  • Known serious hypersensitivity to nemolizumab-ilto or any component of the formulation

For Prurigo Nodularis

The most commonly reported adverse reactions include:

  • Headache
  • Atopic dermatitis
  • Injection-site reactions
  • Eczema

For Atopic Dermatitis

The most commonly reported adverse reactions include:

  • Headache
  • Injection-site reactions
  • Arthralgia (joint pain)
  • Urticaria (hives)

Patients should notify their healthcare provider if they experience persistent injection-site reactions, severe allergic symptoms, or worsening skin or eye symptoms during treatment.

Patients should discuss the following risks with their healthcare provider:

  • Hypersensitivity reactions, including serious allergic reactions
  • Development of conjunctivitis or other ocular disorders
  • Parasitic (helminth) infections
  • Appropriate vaccination before beginning treatment
  • Avoidance of live vaccines during therapy
  • Temporary discontinuation of Nemluvio if a clinically significant hypersensitivity reaction occurs

Patients who develop a helminth infection that does not respond to anti-helminth treatment should discontinue Nemluvio until the infection resolves.

Available human data are insufficient to determine whether Nemluvio increases the risk of major birth defects, miscarriage, or other adverse pregnancy outcomes. As an IgG monoclonal antibody, nemolizumab may cross the placenta, particularly during the third trimester. Patients who are pregnant or planning pregnancy should discuss the potential risks and benefits of treatment with their healthcare provider.

It is not known whether nemolizumab-ilto is present in human milk. The benefits of breastfeeding should be weighed against the mother’s clinical need for Nemluvio and any potential adverse effects on the breastfed infant. Patients should discuss breastfeeding plans with their healthcare provider.

No formal clinical drug interaction studies have demonstrated clinically significant pharmacokinetic interactions. Healthcare providers should review all medications, particularly:

  • Live vaccines (should generally be avoided during treatment)
  • Concomitant biologic or immunosuppressive therapies, which should be evaluated on an individual basis by the treating healthcare provider

Nemluvio is administered by subcutaneous injection. An initial loading dose is administered according to the FDA-approved prescribing information, followed by maintenance injections generally every 4 weeks. It may be administered by a healthcare provider or, after appropriate training, by patients or caregivers when appropriate. Allow the prefilled pen or prefilled syringe to reach room temperature before administration according to the prescribing information. Do not heat using external heat sources. Recommended injection sites include the abdomen, thigh, or upper arm (when administered by another person). Rotate injection sites and avoid injecting into damaged, bruised, tender, or scarred skin.

Access to Multiple Medications

Support Beyond Nemluvio

Some patients may need multiple medication assistance programs to access all of their brand-name medications.

Prescription Hope can help.

With a list of hundreds of available medications, our team of patient advocates may be able to help with some, if not all, of your brand-name medications.

And no matter how many medications, our service rate is a simple $70.00 per month, per medication.

Why Choose Prescription Hope

Patient-Focused Medication Support

Our patient-centered prescription help has offered advocacy and support to Americans for over 20 years.

Simplified Access to Prescription Medications

Prescription Hope’s access to affordable Nemluvio for a simple $70.00 per month, per medication.

Ongoing Prescription Assistance

Our advocacy and support don’t end when your application is complete. We provide long-term medication support for as long as you are a patient with us. We handle all associated administrative tasks, including document updates, issue resolution, yearly renewals, refill scheduling, and more.

If you’re looking to enroll in the Nemluvio Patient Assistance Program through Prescription Hope, then be sure to fill out our enrollment form today and find out how we can help you save on your monthly medication costs!

 

Frequently Asked Questions

It's Easy!

Submit Enrollment Form

Getting started is free and easy! Simply complete the online enrollment form. 

Receive Welcome Call

An Enrollment Specialist will reach out to you for a personalized welcome call.

We Manage The Process

Your dedicated team manages your account month after month, allowing you to focus on what matters most—your health.

Helpful Articles

Latest News & Stories

Save Money On Your Prescriptions Today!